Shares of Novavax Inc. NVAX slid 2.28% to $6.85 Wednesday, on what proved to be an all-around mixed trading session for the ...

Vinay Prasad resigns from the FDA after backlash over vaccine restrictions and gene therapy decisions. Political pressure cited in sudden departure.

Prasad’s short FDA tenure brought stricter review standards for gene and COVID vaccines, sparking biotech concern and political backlash.

Vinay Prasad, who headed the U.S. FDA division in charge of vaccines and was also chief medical and scientific officer, has ...

Dr. Vinay Prasad, the chief scientific officer at the Food and Drug Administration, has resigned after only three months in ...

Vinay Prasad, who came under fire from patient advocacy groups and Laura Loomer, is gone after less than three months on the ...

Dr. Vinay Prasad had been serving as the FDA's director of the Center for Biologics Evaluation and Research since May, and ...

After just a few controversial months, Vinay Prasad, MD, MPH, has stepped down as director of FDA's Center for Biologics ...

Vinay Prasad resigned from the FDA after just two months in the role, following backlash over blocking access to Sarepta’s ...

After losing 3,500 employees in April—19% of its workforce due to congressional budget cuts—the FDA is now struggling to meet ...

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

US Health Secretary Robert F. Kennedy Jr.’s vaccine policies and commentary largely appear to contradict his pledge to revamp ...